Study in Healthy Males to Assess Bioavailability of Single Fostamatinib With iv Micro Tracer Dose

Sponsor
AstraZeneca
Study ID
NCT01598571
Phase
PHASE1
Status
Completed

Conditions

  • Healthy

Eligibility Criteria

Sex
MALE
Age
18 Years - 55 Years
Healthy Volunteers
Accepted

Interventions

  • Fostamatinib — DRUG
    Fostamatinib 50 mg tablet
  • Fostamatinib — DRUG
    Fostamatinib 100 μg \[14C\] R406 intravenous micro tracer dose

Study Details

Study in healthy males to assess bioavailability of single fostamatinib with iv micro tracer dose.

Key Dates

Start date
May 31, 2012
Status verified
Aug 2012
Primary completion
Aug 31, 2012
Completion
Aug 31, 2012

Study Design

Enrollment
37 participants (actual)
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
BASIC_SCIENCE

Arms

  • Experimental: Fostamatinib 50 mg tablet
  • Experimental: Fostamatinib 100 μg [14C] R406 intravenous micro tracer dose

Primary Outcome Measure

The percent of absolute bioavailability (F) of R406 after oral administration of fostamatinib. [ Time Frame: Up to 96 hours post dose ]

Related Studies